Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study

Highlights • SH after chemo-immunotherapy is a risk factor for iNHL patients. • Our study investigated incidence and risk factors for SH, infective complications. • Incidence of SH was 2.2 × 1000 person-years. • Exposure to Fbs ± R and ASCT was statistically associated with SH incidence. • Exposure...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2015-12, Vol.39 (12), p.1382-1388
Main Authors: De Angelis, Federico, Tosti, Maria Elena, Capria, Saveria, Russo, Eleonora, D’Elia, Gianna Maria, Annechini, Giorgia, Stefanizzi, Caterina, Foà, Robin, Pulsoni, Alessandro
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bone Marrow - pathology
Cyclophosphamide - administration & dosage
Disease Susceptibility
Doxorubicin - administration & dosage
Female
Fludarabine
Hematology, Oncology and Palliative Medicine
Hematopoietic Stem Cell Transplantation
Humans
Hypogammaglobulinemia
IgG Deficiency - chemically induced
IgG Deficiency - epidemiology
Immunocompromised Host
Immunotherapy - adverse effects
Incidence
Kaplan-Meier Estimate
Lymphoma, Non-Hodgkin - drug therapy
Lymphoma, Non-Hodgkin - pathology
Lymphoma, Non-Hodgkin - therapy
Male
Middle Aged
Non-Hodgkin lymphoma
Pneumonia - etiology
Prednisone - administration & dosage
Proportional Hazards Models
Retrospective Studies
Rituximab
Rituximab - administration & dosage
Rituximab - adverse effects
Transplantation, Autologous
Vidarabine - administration & dosage
Vidarabine - adverse effects
Vidarabine - analogs & derivatives
Vincristine - administration & dosage
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • SH after chemo-immunotherapy is a risk factor for iNHL patients. • Our study investigated incidence and risk factors for SH, infective complications. • Incidence of SH was 2.2 × 1000 person-years. • Exposure to Fbs ± R and ASCT was statistically associated with SH incidence. • Exposure to CHOP ± R or CVP ± R was not a risk factor as well as Rituximab exposure.
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2015.10.013